BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64:2077-2088. [PMID: 27178646 DOI: 10.1002/hep.28643] [Cited by in Crossref: 148] [Cited by in F6Publishing: 146] [Article Influence: 24.7] [Reference Citation Analysis]
Number Citing Articles
1 Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, Murad MH, Mohammed K. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology. 2018;67:381-400. [PMID: 28859222 DOI: 10.1002/hep.29485] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 17.2] [Reference Citation Analysis]
2 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Rauchfuß F, Dondorf F, Fahrner R, Tautenhahn HM, Ardelt M, Settmacher U. Searching the ideal hepatocellular carcinoma patient for liver transplantation: are the Toronto criteria a step in the right direction? Hepatobiliary Surg Nutr 2017;6:342-3. [PMID: 29152484 DOI: 10.21037/hbsn.2017.05.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
5 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Schoenberg MB, Anger HJW, Bucher JN, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. Visc Med 2020;36:506-15. [PMID: 33447607 DOI: 10.1159/000506752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Chen K, Gorgen A, Ding A, Du L, Jiang K, Ding Y, Sapisochin G, Ghanekar A. Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma. Hepatol Commun 2021;5:1310-28. [PMID: 34278178 DOI: 10.1002/hep4.1701] [Reference Citation Analysis]
9 Zhang J, Yu Z, Li H, Yi S, Liu W, Yang Y, Wang G. Severe bile duct complication after yttrium-90 radioembolization therapy in a patient with recurrent hepatocellular carcinoma after liver transplantation: A case report. Liver Research 2021;5:33-5. [DOI: 10.1016/j.livres.2020.10.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, Ghanekar A, Lilly L, Cattral M, Galvin Z, Selzner M, Bhat M, Selzner N, Mcgilvray I, Greig PD, Grant DR, Sapisochin G. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. Journal of Hepatology 2019;70:666-73. [DOI: 10.1016/j.jhep.2018.12.029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
11 Piñero F, Carrihlo FJ, Silva MO. Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: Still an unmet need. Liver Int 2017;37:648-50. [PMID: 28453922 DOI: 10.1111/liv.13417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Bae JS, Lee DH, Lee SM, Suh KS, Lee KW, Yi NJ, Lee KB, Kim H, Han JK. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplantation According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol 2022. [PMID: 35138137 DOI: 10.2214/AJR.21.27186] [Reference Citation Analysis]
13 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
14 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019; 11(1): 50-64 [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
15 El-Domiaty N, Saliba F, Vibert E, Karam V, Sobesky R, Ibrahim W, Pittau G, Ciacio O, Salloum C, Amer K, Saeed MA, Shawky JA, Sa Cunha A, Rosmorduc O, Cherqui D, Adam R, Samuel D. Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome. Transplantation 2021;105:1778-90. [PMID: 32890134 DOI: 10.1097/TP.0000000000003434] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Barry A, Apisarnthanarax S, O'Kane GM, Sapisochin G, Beecroft R, Salem R, Yoon SM, Lim YS, Bridgewater J, Davidson B, Scorsetti M, Solbiati L, Diehl A, Schuffenegger PM, Sham JG, Cavallucci D, Galvin Z, Dawson LA, Hawkins MA. Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. Lancet Gastroenterol Hepatol. 2020;5:765-775. [PMID: 32511951 DOI: 10.1016/s2468-1253(20)30182-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
17 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Reference Citation Analysis]
18 Bauschke A, Altendorf-Hofmann A, Kissler H, Koch A, Malessa C, Settmacher U. Validity of eleven prognostic scores with respect to intra- and extrahepatic recurrence of hepatocellular carcinoma after liver transplantation. J Cancer Res Clin Oncol 2017;143:2595-605. [PMID: 28849266 DOI: 10.1007/s00432-017-2507-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Halazun KJ, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, Samstein B, Brown RS, Emond JC, Busuttil RW, Agopian VG. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg. 2018;268:690-699. [PMID: 30048307 DOI: 10.1097/sla.0000000000002964] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 11.3] [Reference Citation Analysis]
20 Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig PD, Knox JJ, Dawson LA, Grant DR. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67:92-99. [PMID: 28257902 DOI: 10.1016/j.jhep.2017.02.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 99] [Article Influence: 22.6] [Reference Citation Analysis]
21 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Liu S, Nalesnik MA, Singhi A, Wood-Trageser MA, Randhawa P, Ren BG, Humar A, Liu P, Yu YP, Tseng GC, Michalopoulos G, Luo JH. Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients. Hepatol Commun 2021. [PMID: 34725972 DOI: 10.1002/hep4.1846] [Reference Citation Analysis]
24 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Limkemann AJ, Abreu P, Sapisochin G. How far can we go with hepatocellular carcinoma in living donor liver transplantation?: . Current Opinion in Organ Transplantation 2019;24:644-50. [DOI: 10.1097/mot.0000000000000692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
26 Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol 2021. [PMID: 34117916 DOI: 10.1007/s00432-021-03665-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Martins-Filho SN, Alves VAF, Wakamatsu A, Maeda M, Craig AJ, Assato AK, Villacorta-Martin C, D'Avola D, Labgaa I, Carrilho FJ, Thung SN, Villanueva A. A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology. 2019;74:718-730. [PMID: 30636011 DOI: 10.1111/his.13809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
28 Uchiyama H, Itoh S, Yoshizumi T, Ikegami T, Harimoto N, Soejima Y, Harada N, Morita K, Toshima T, Motomura T. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years. HPB (Oxford). 2017;19:1082-1090. [PMID: 28888776 DOI: 10.1016/j.hpb.2017.08.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
29 Mullath A, Krishna M. Hepatocellular carcinoma – time to take the ticket. World J Gastrointest Surg 2019; 11(6): 287-295 [PMID: 31367276 DOI: 10.4240/wjgs.v11.i6.287] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
30 Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J;  iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64:1178-1188. [PMID: 27481548 DOI: 10.1002/hep.28744] [Cited by in Crossref: 132] [Cited by in F6Publishing: 112] [Article Influence: 22.0] [Reference Citation Analysis]
31 Ohira M, Tanimine N, Kobayashi T, Ohdan H. Essential updates 2018/2019: Liver transplantation. Ann Gastroenterol Surg 2020;4:195-207. [PMID: 32490333 DOI: 10.1002/ags3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ma KW, Chok KSH, Fung JYY, Lo CM. Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. J Clin Transl Hepatol 2018;6:283-8. [PMID: 30271740 DOI: 10.14218/JCTH.2017.00058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Firl DJ, Sasaki K, Agopian VG, Gorgen A, Kimura S, Dumronggittigule W, Mcvey JC, Iesari S, Mennini G, Vitale A, Finkenstedt A, Onali S, Hoppe‐lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Agnes S, Vivarelli M, Tisone G, Ettorre GM, Otto G, Tsochatzis E, Rossi M, Viveiros A, Cillo U, Markmann JF, Ikegami T, Kaido T, Lai Q, Sapisochin G, Lerut J, Aucejo FN; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology 2019;71:569-82. [DOI: 10.1002/hep.30838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
34 Mulligan DC. The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to Toronto and beyond: Mulligan. Hepatology 2016;64:1853-5. [DOI: 10.1002/hep.28841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Liu K, McCaughan GW. How to select the appropriate "neoadjuvant therapy" for hepatocellular carcinoma. Expert Opin Pharmacother 2018;19:1167-70. [PMID: 30011239 DOI: 10.1080/14656566.2018.1498843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Ogut Z, Kilci B, Ince V, Koc C, Isik B, Yilmaz S. Very Rare Recurrence Site of Hepatocellular Carcinoma After Living Donor Liver Transplantation: Subcutaneous Abdominal Drain Tract. J Gastrointest Cancer 2021;52:310-2. [PMID: 32495110 DOI: 10.1007/s12029-020-00429-5] [Reference Citation Analysis]
37 Ju MR, Yopp AC. Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience. Ann Gastroenterol Surg 2020;4:208-15. [PMID: 32490334 DOI: 10.1002/ags3.12316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Di Maira T, Sapisochin G, Lilly L, Fonés V, Berenguer M. Posttransplant Calcineurin Inhibitors Levels and Intrapatient Variability Are Not Associated With Long-term Outcomes Following Liver Transplantation. Transplantation 2020;104:1201-9. [PMID: 31609904 DOI: 10.1097/TP.0000000000002987] [Reference Citation Analysis]
39 Vishnevsky VA, Ayvazyan KA, Ikramov RZ, Ionkin DA, Zhavoronkova OI, Stepanova YA, Varava AB, Kovalenko YA, Zharikov YO, Goncharov AB, Olifir AA, Pakhomova AY, Bugaev SA, Zhao AV. Modern principles of hepatocellular carcinoma treatment. Ann hir gepatol 2020;25:15-26. [DOI: 10.16931/1995-5464.2020215-26] [Reference Citation Analysis]
40 Seehofer D, Petrowsky H, Schneeberger S, Vibert E, Ricke J, Sapisochin G, Nault J, Berg T. Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation—Adjusting the Odds? Transpl Int 2022;35:10333. [DOI: 10.3389/ti.2022.10333] [Reference Citation Analysis]
41 Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, Xu X. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2020;33:697-712. [PMID: 31985857 DOI: 10.1111/tri.13585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
42 Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Front Oncol 2020;10:616094. [PMID: 33598433 DOI: 10.3389/fonc.2020.616094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yilmaz C, Karaca CA, Iakobadze Z, Farajov R, Kilic K, Doganay L, Kilic M. Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma. Transplant Proc. 2018;50:3571-3576. [PMID: 30577240 DOI: 10.1016/j.transproceed.2018.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
44 Rudnick SR, Russo MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2018;12:265-75. [PMID: 29231769 DOI: 10.1080/17474124.2018.1417035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
45 Schoenberg MB, Ehmer U, Umgelter A, Bucher JN, Koch DT, Börner N, Nieß H, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver transplantation versus watchful waiting in hepatocellular carcinoma patients with complete response to bridging therapy - a retrospective observational study. Transpl Int 2021;34:465-73. [PMID: 33368655 DOI: 10.1111/tri.13808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol 2020;8:69-75. [PMID: 32274347 DOI: 10.14218/JCTH.2019.00050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
47 Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:6307. [PMID: 34944927 DOI: 10.3390/cancers13246307] [Reference Citation Analysis]
48 Azhie A, Grant RC, Herman M, Wang L, Knox JJ, Bhat M. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncol 2022. [PMID: 35287469 DOI: 10.2217/fon-2021-1635] [Reference Citation Analysis]
49 Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl 2018;24:369-79. [PMID: 29140601 DOI: 10.1002/lt.24977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
50 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol 2018; 10(2): 308-318 [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
51 Dakua SP, Nayak A. A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00191-2] [Reference Citation Analysis]
52 Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation 2020;104:2087-96. [PMID: 31978002 DOI: 10.1097/TP.0000000000003115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Biolato M, Galasso T, Marrone G, Miele L, Grieco A. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers (Basel) 2021;13:6337. [PMID: 34944957 DOI: 10.3390/cancers13246337] [Reference Citation Analysis]
54 Bhangui P, Saigal S, Gautam D, Piplani T, Choudhary N, Chaudhary R, Yadav S, Thiagarajan S, Rastogi A, Saraf N, Nundy S, Soin AS. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria. Liver Transpl 2021;27:209-21. [PMID: 33253492 DOI: 10.1002/lt.25956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
55 Bhatti ABH, Waheed A, Khan NA. Living Donor Liver Transplantation for Hepatocellular Carcinoma: Appraisal of the United Network for Organ Sharing Modified TNM Staging. Front Surg 2020;7:622170. [PMID: 33553240 DOI: 10.3389/fsurg.2020.622170] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Ince V, Akbulut S, Otan E, Ersan V, Karakas S, Sahin TT, Carr BI, Baskiran A, Samdanci E, Bag HG, Koc C, Usta S, Ozdemir F, Barut B, Gonultas F, Sarici B, Kutluturk K, Dogan MS, Ozgor D, Dikilitas M, Harputluoglu M, Aladag M, Kutlu R, Varol I, Dirican A, Aydin C, Isik B, Ara C, Kayaalp C, Emre S, Yilmaz S. Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. J Gastrointest Cancer. 2020;51:998-1005. [PMID: 32519232 DOI: 10.1007/s12029-020-00424-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
57 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
58 Dageforde LA, Fowler KJ, Chapman WC. Liver transplantation for hepatocellular carcinoma: current update on treatment and allocation. Curr Opin Organ Transplant 2017;22:128-34. [PMID: 27926548 DOI: 10.1097/MOT.0000000000000385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
59 Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis 2021;41:117-27. [PMID: 33788207 DOI: 10.1055/s-0040-1716565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Tohyama T, Sakamoto K, Tamura K, Nakamura T, Watanabe J, Wakisaka H, Takada Y. Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review. World J Surg Oncol 2020;18:109. [PMID: 32466780 DOI: 10.1186/s12957-020-01873-0] [Reference Citation Analysis]
62 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
63 Abreu P, Gorgen A, Griffiths C, Ivanics T, Sapisochin G. Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. Curr Hepatology Rep 2019;18:400-7. [DOI: 10.1007/s11901-019-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Zhou K, Mehta N. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis 2020;24:665-79. [PMID: 33012452 DOI: 10.1016/j.cld.2020.07.005] [Reference Citation Analysis]
65 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
66 Colombo M, Torzilli G. Expanding transplantation of patients with a liver cancer without harming allocation: a priority in the era of scarce donation. Hepatobiliary Surg Nutr 2017;6:339-41. [PMID: 29152483 DOI: 10.21037/hbsn.2017.05.13] [Reference Citation Analysis]
67 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
69 Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. Dig Dis Sci 2020;65:647-57. [PMID: 31440998 DOI: 10.1007/s10620-019-05781-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
71 Sun Y, Zou H, Yang L, Zhou M, Shi X, Yang Y, Chen W, Zhao Y, Mo J, Lu Y. Effect on the liver cancer cell invasion ability by studying the associations between autophagy and TRAP1 expression. Oncol Lett 2018;16:991-7. [PMID: 29963174 DOI: 10.3892/ol.2018.8774] [Reference Citation Analysis]
72 Dirican A, Karakas S. What Should Be the Rules for Downstaging for Hepatocellular Carcinoma? J Gastrointest Cancer 2020;51:1148-51. [PMID: 32839945 DOI: 10.1007/s12029-020-00490-0] [Reference Citation Analysis]
73 Schmelzle M, Krenzien F, Schöning W, Pratschke J. [Treatment of hepatocellular carcinoma in the cirrhotic and non-cirrhotic liver]. Chirurg 2018;89:851-7. [PMID: 30109374 DOI: 10.1007/s00104-018-0690-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
74 Carr BI, Guerra V, Donghia R, Farinati F, Giannini EG, Muratori L, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Campani C, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F. Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. Cancers (Basel) 2021;13:592. [PMID: 33546234 DOI: 10.3390/cancers13040592] [Reference Citation Analysis]
75 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
76 Gundlach JP, Schmidt S, Bernsmeier A, Günther R, Kataev V, Trentmann J, Schäfer JP, Röcken C, Becker T, Braun F. Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence. J Clin Med 2021;10:1155. [PMID: 33801887 DOI: 10.3390/jcm10061155] [Reference Citation Analysis]
77 Balitzer D, Kakar S. Challenges in Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver: A Pathologist's Perspective. Clin Liver Dis (Hoboken) 2021;17:249-54. [PMID: 33968384 DOI: 10.1002/cld.1091] [Reference Citation Analysis]
78 Ng AC. Stick to Milan: Infeasibility of the Brazil-Milan Criteria in recommending patients with hepatocellular carcinoma for liver transplantation. Ann Hepatol 2021;25:100537. [PMID: 34547478 DOI: 10.1016/j.aohep.2021.100537] [Reference Citation Analysis]
79 Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Saharia A, McMillan R, Victor D, Kodali S, Shetty A, Nolte Fong JV, Moore LW, Heyne K, Gaber AO, Ghobrial RM. Transplant Oncology: An Evolving Field in Cancer Care. Cancers (Basel) 2021;13:4911. [PMID: 34638395 DOI: 10.3390/cancers13194911] [Reference Citation Analysis]
80 Goldaracena N, Barbas AS. Living donor liver transplantation. Curr Opin Organ Transplant. 2019;24:131-137. [PMID: 30694993 DOI: 10.1097/mot.0000000000000610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Peloso A, Oldani G. Enlarged selection criteria for hepatocellular cancer: is the upper limit needed? Transl Gastroenterol Hepatol 2017;2:73. [PMID: 29034346 DOI: 10.21037/tgh.2017.09.02] [Reference Citation Analysis]
82 Tang JC, Wu K, Zheng X, Xu M, Dai Y, Wei SS, Cai XJ. GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy. Chin Med J (Engl) 2019;132:311-8. [PMID: 30681497 DOI: 10.1097/CM9.0000000000000053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Aravinthan AD, Bruni SG, Doyle AC, Thein HH, Goldaracena N, Issachar A, Lilly LB, Selzner N, Bhat M, Sreeharsha B, Selzner M, Ghanekar A, Cattral MS, McGilvray ID, Greig PD, Renner EL, Grant DR, Sapisochin G. Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:1843-51. [PMID: 28160137 DOI: 10.1245/s10434-017-5789-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
84 Burra P, Zanetto A, Gambato M. Extending transplantation criteria for hepatocellular carcinoma. Lancet Gastroenterol Hepatol 2017;2:546-7. [PMID: 28546008 DOI: 10.1016/S2468-1253(17)30143-7] [Reference Citation Analysis]
85 Toniutto P, Fumolo E, Fornasiere E, Bitetto D. Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J Clin Med 2021;10:3932. [PMID: 34501381 DOI: 10.3390/jcm10173932] [Reference Citation Analysis]
86 Gorgen A, Rosales R, Sadler E, Beecroft R, Knox J, Dawson LA, Ghanekar A, Grant D, Greig PD, Sapisochin G. Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplantation 2019;103:2136-43. [DOI: 10.1097/tp.0000000000002616] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
88 Muaddi H, Al-Adra DP, Beecroft R, Ghanekar A, Moulton CA, Doyle A, Selzner M, Wei A, McGilvray ID, Gallinger S, Grant DR, Cattral MS, Greig PD, Kachura J, Cleary SP, Sapisochin G. Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent. Ann Surg Oncol. 2018;25:991-999. [PMID: 29327179 DOI: 10.1245/s10434-017-6329-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
89 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
90 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
92 Magro B, Pinelli D, De Giorgio M, Lucà MG, Ghirardi A, Carrobio A, Baronio G, Del Prete L, Nounamo F, Gianatti A, Colledan M, Fagiuoli S. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria. Cancers (Basel) 2021;13:5976. [PMID: 34885087 DOI: 10.3390/cancers13235976] [Reference Citation Analysis]
93 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
94 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Fauda M, McCormack L, Gadano A, Boin IS, García JHP, Silva M. Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study. Ann Hepatol 2018;17:256-67. [PMID: 29469048 DOI: 10.5604/01.3001.0010.8648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
95 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
96 Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018;102:640-647. [PMID: 29319620 DOI: 10.1097/tp.0000000000002043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
97 Grąt M, Stypułkowski J, Patkowski W, Wronka KM, Bik E, Krasnodębski M, Masior Ł, Lewandowski Z, Wasilewicz M, Grąt K, Krawczyk M, Zieniewicz K. Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer. Ann Surg Oncol 2017;24:3188-95. [PMID: 28695391 DOI: 10.1245/s10434-017-5989-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
98 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
99 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019;69:1193-205. [PMID: 30548884 DOI: 10.1002/hep.30413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
100 Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol 2017;2:80. [PMID: 29167827 DOI: 10.21037/tgh.2017.09.06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
101 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Reference Citation Analysis]
102 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
103 D'Avola D, Bilbao JI, Sangro B. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. Cardiovasc Intervent Radiol 2019;42:1262-70. [PMID: 31069465 DOI: 10.1007/s00270-019-02221-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
104 Degroote H, Callebout E, Iesari S, Dekervel J, Schreiber J, Pirenne J, Verslype C, Ysebaert D, Michielsen P, Lucidi V, Moreno C, Detry O, Delwaide J, Troisi RI, Lerut JP, Van Vlierberghe H; Be-LIAC. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2020;33:231-8. [PMID: 31630912 DOI: 10.1016/j.suronc.2019.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
105 Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953] [Reference Citation Analysis]
106 Bhat M, Clotet-Freixas S, Baciu C, Pasini E, Hammad A, Ivanics T, Reid S, Azhie A, Angeli M, Ghanekar A, Fischer S, Sapisochin G, Konvalinka A. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan. Clin Proteomics 2021;18:27. [PMID: 34794390 DOI: 10.1186/s12014-021-09333-x] [Reference Citation Analysis]
107 Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S;  Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32:356-368. [PMID: 30556935 DOI: 10.1111/tri.13391] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
108 Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018;24:327-329. [PMID: 29351366 DOI: 10.1002/lt.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
109 Ince V, Carr BI, Bag HG, Ersan V, Usta S, Koc C, Gonultas F, Sarici BK, Karakas S, Kutluturk K, Baskiran A, Yilmaz S. Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha-fetoprotein, a retrospective cohort study. World J Gastrointest Surg 2020; 12(12): 520-533 [PMID: 33437403 DOI: 10.4240/wjgs.v12.i12.520] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
110 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, Gautam D, Choudhary NS, Thiagarajan S, Rastogi A, Saraf N, Saigal S. Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging. Transplantation 2020;104:2334-45. [PMID: 32032291 DOI: 10.1097/TP.0000000000003162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
112 Guerrini GP, Berretta M, Guaraldi G, Magistri P, Esposito G, Ballarin R, Serra V, Di Sandro S, Di Benedetto F. Liver Transplantation for HCC in HIV-Infected Patients: Long-Term Single-Center Experience. Cancers (Basel) 2021;13:4727. [PMID: 34572954 DOI: 10.3390/cancers13184727] [Reference Citation Analysis]
113 Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastro 2017;15:296-304. [DOI: 10.1007/s11938-017-0133-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
114 Orci LA, Combescure C, Fink M, Oldani G, Compagnon P, Andres A, Berney T, Toso C. Predicting recurrence of hepatocellular carcinoma after liver transplantation using a novel model that incorporates tumor and donor-related factors. Transpl Int 2021. [PMID: 34784081 DOI: 10.1111/tri.14161] [Reference Citation Analysis]
115 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Lee-Ying R, Ahmed O, Ahmed S, Ahmed S, Bathe OF, Brunet B, Dawson L, Davies J, Gordon V, Hebbard P, Kasnik J, Kim CA, Le D, Lee MKC, Lim H, McGhie JP, Mulder K, Park J, Renouf D, Tam V, Visser R, Wong RPW, Zaidi A, Doll C. Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019. Curr Oncol 2021;28:3629-48. [PMID: 34590606 DOI: 10.3390/curroncol28050310] [Reference Citation Analysis]
117 Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 2019;70:866-73. [PMID: 30615906 DOI: 10.1016/j.jhep.2018.12.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
118 Nevarez NM, Yopp AC. Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Hepatocell Carcinoma 2021;8:851-60. [PMID: 34350140 DOI: 10.2147/JHC.S291530] [Reference Citation Analysis]
119 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018; 24(32): 3626-3636 [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
120 Grąt M, Stypułkowski J, Patkowski W, Bik E, Krasnodębski M, Wronka KM, Lewandowski Z, Wasilewicz M, Grąt K, Masior Ł, Ligocka J, Krawczyk M. Limitations of predicting microvascular invasion in patients with hepatocellular cancer prior to liver transplantation. Sci Rep 2017;7:39881. [PMID: 28057916 DOI: 10.1038/srep39881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
121 Yilmaz S, Sahin T, Saglam K. What Are the Immune Obstacles to Liver Xenotransplantation Which Is Promising for Patients with Hepatocellular Carcinoma? J Gastrointest Cancer 2020;51:1209-14. [PMID: 32833222 DOI: 10.1007/s12029-020-00495-9] [Reference Citation Analysis]
122 Moghe A, Ganesh S, Humar A, Molinari M, Jonassaint N. Expanding Donor Selection and Recipient Indications for Living Donor Liver Transplantation. Clin Liver Dis 2021;25:121-35. [PMID: 33978574 DOI: 10.1016/j.cld.2020.08.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
124 Ma KW, Cheung TT. When to consider liver transplantation in hepatocellular carcinoma patients? Hepat Oncol. 2017;4:15-24. [PMID: 30191050 DOI: 10.2217/hep-2016-0010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
125 Zeair S, Rajchert J, Stasiuk R, Cyprys S, Miętkiewski J, Zasada-Cedro K, Karpińska E, Duczkowska M, Parczewski M, Wawrzynowicz-Syczewska M. Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience. Ann Transplant 2019;24:499-505. [PMID: 31439828 DOI: 10.12659/AOT.918150] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
126 Herden U, Schoening W, Pratschke J, Manekeller S, Paul A, Linke R, Lorf T, Lehner F, Braun F, Stippel DL, Sucher R, Schmidt H, Strassburg CP, Guba M, van Rosmalen M, Rogiers X, Samuel U, Schön GM, Nashan B. Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study. Can J Gastroenterol Hepatol 2019;2019:8747438. [PMID: 30949459 DOI: 10.1155/2019/8747438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Grąt M, Stypułkowski J, Morawski M, Wronka KM, Wasilewicz M, Lewandowski Z, Grąt K, Wójcik Z, Patkowski W, Zieniewicz K. Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation. Ann Surg 2020;271:1124-31. [PMID: 30601254 DOI: 10.1097/SLA.0000000000003176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
128 Kirchner VA, Goldaracena N, Sapisochin G, Alejandro RH, Shah SA. Current status of liver transplantation in North America. Int J Surg 2020;82S:9-13. [PMID: 32473238 DOI: 10.1016/j.ijsu.2020.05.059] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Tschuor C, Ferrarese A, Kuemmerli C, Dutkowski P, Burra P, Clavien PA;  Liver Allocation Study Group. Allocation of liver grafts worldwide - Is there a best system? J Hepatol. 2019;71:707-718. [PMID: 31199941 DOI: 10.1016/j.jhep.2019.05.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
130 Wallace D, Cowling TE, Walker K, Suddle A, Rowe I, Callaghan C, Gimson A, Bernal W, Heaton N, van der Meulen J. Short- and long-term mortality after liver transplantation in patients with and without hepatocellular carcinoma in the UK. British Journal of Surgery 2020;107:896-905. [DOI: 10.1002/bjs.11451] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
131 Reichman TW, Bhati CS, Battula NR. Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer. Dig Dis Sci 2019;64:976-84. [PMID: 30840163 DOI: 10.1007/s10620-019-05550-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Doğan SM, Kutlutürk K. Living Donor Versus Deceased Donor Liver Transplantation for HCC. J Gastrointest Cancer 2020;51:1104-6. [PMID: 32833221 DOI: 10.1007/s12029-020-00481-1] [Reference Citation Analysis]
133 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Reference Citation Analysis]
134 Ivanics T, Nelson W, Patel MS, Claasen MPAW, Lau L, Gorgen A, Abreu P, Goldenberg A, Erdman L, Sapisochin G. The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach. Liver Transpl 2021. [PMID: 34626159 DOI: 10.1002/lt.26332] [Reference Citation Analysis]
135 Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant 2021;26:168-75. [PMID: 33650998 DOI: 10.1097/MOT.0000000000000866] [Reference Citation Analysis]
136 Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical Treatments of Hepatobiliary Cancers. Hepatology 2021;73 Suppl 1:128-36. [PMID: 32438491 DOI: 10.1002/hep.31325] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
137 Chen W, Chen X, Li S, Ren B. Expression, immune infiltration and clinical significance of SPAG5 in hepatocellular carcinoma: A gene expression-based study. J Gene Med 2020;22:e3155. [PMID: 31860771 DOI: 10.1002/jgm.3155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
139 Mu HN, Li Q, Fan JY, Pan CS, Liu YY, Yan L, Sun K, Hu BH, Huang DD, Zhao XR, Chang X, Wang CS, He SY, He K, Yang BX, Han JY. Caffeic acid attenuates rat liver injury after transplantation involving PDIA3-dependent regulation of NADPH oxidase. Free Radic Biol Med 2018;129:202-14. [PMID: 30218773 DOI: 10.1016/j.freeradbiomed.2018.09.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
140 Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:498-502. [PMID: 28124007 DOI: 10.21037/hbsn.2016.12.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
141 Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. [PMID: 31436873 DOI: 10.1111/liv.14223] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
142 Ince V, Ara C, Yilmaz S. Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1118-21. [PMID: 32860615 DOI: 10.1007/s12029-020-00484-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Wang YF, Dai YH, Lin CS, Chang HC, Shen PC, Yang JF, Hsiang CW, Lo CH, Huang WY. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series. Radiat Oncol 2021;16:15. [PMID: 33446231 DOI: 10.1186/s13014-020-01739-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
144 Yopp AC, Marrero JA, Singal AG. Expansion of Criteria for Liver Transplantation in Hepatocellular Carcinoma: Better Patient Selection or a Slippery Slope? Ann Surg Oncol 2017;24:1758-60. [DOI: 10.1245/s10434-017-5802-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
145 Usta S, Kayaalp C. Tumor Diameter for Hepatocellular Carcinoma: Why Should Size Matter? J Gastrointest Cancer 2020;51:1114-7. [PMID: 32851543 DOI: 10.1007/s12029-020-00483-z] [Reference Citation Analysis]
146 Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, Sapena V, Díaz A, Vilana R, Navasa M, Fondevila C, Miquel R, Ayuso C, García-Valdecasas JC, Bruix J, Reig M, Fuster J. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol 2021:S0168-8278(21)00435-9. [PMID: 34171433 DOI: 10.1016/j.jhep.2021.06.015] [Reference Citation Analysis]
147 Giorgakis E, Khorsandi SE, Mathur AK, Burdine L, Jassem W, Heaton N. Comparable graft survival is achievable with the usage of donation after circulatory death liver grafts from donors at or above 70 years of age: A long-term UK national analysis. Am J Transplant 2021;21:2200-10. [PMID: 33222386 DOI: 10.1111/ajt.16409] [Reference Citation Analysis]
148 Viveiros A, Zoller H, Finkenstedt A. Hepatocellular carcinoma: when is liver transplantation oncologically futile? Transl Gastroenterol Hepatol 2017;2:63. [PMID: 28815223 DOI: 10.21037/tgh.2017.07.03] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
149 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
150 Salehi O, Vega EA, Kutlu OC, Lunsford K, Freeman R, Ladin K, Alarcon SV, Kazakova V, Conrad C. Poorly differentiated hepatocellular carcinoma: resection is equivalent to transplantation in patients with low liver fibrosis. HPB (Oxford) 2021:S1365-182X(21)01727-5. [PMID: 34969618 DOI: 10.1016/j.hpb.2021.12.001] [Reference Citation Analysis]
151 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019; 25(21): 2591-2602 [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
152 Lurje G, Bednarsch J, Czigany Z, Amygdalos I, Meister F, Schöning W, Ulmer TF, Foerster M, Dejong C, Neumann UP. Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent. Langenbecks Arch Surg 2018;403:851-61. [DOI: 10.1007/s00423-018-1715-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
153 Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken) 2019;13:20-5. [PMID: 31168361 DOI: 10.1002/cld.793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
154 Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M. New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transpl 2019;25:311-22. [PMID: 30317696 DOI: 10.1002/lt.25354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
155 Polat KY, Acar S, Gencdal G, Yazar S, Kargi A, Donmez R, Aslan S, Kavlak ME, Arikan C, Akyildiz M. Hepatocellular Carcinoma and Liver Transplantation: A Single-Center Experience. Transplantation Proceedings 2020;52:259-64. [DOI: 10.1016/j.transproceed.2019.10.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
156 Felgendreff P, Raschzok N, Kunze K, Leder A, Lippert S, Klunk S, Tautenhahn H, Hau H, Schmuck RB, Reutzel-selke A, Sauer IM, Bartels M, Morgül MH. Tissue-based miRNA mapping in alcoholic liver cirrhosis: different profiles in cirrhosis with or without hepatocellular carcinoma. Biomarkers 2020;25:62-8. [DOI: 10.1080/1354750x.2019.1691267] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
158 Heimbach JK. Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy for Patients with Hepatocellular Carcinoma. Semin Liver Dis 2020;40:358-64. [PMID: 32942324 DOI: 10.1055/s-0040-1709492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Martins-filho SN, Alves VAF. The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review. Surg Exp Pathol 2019;2. [DOI: 10.1186/s42047-019-0047-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Nitta H, Younès A, El-Domiaty N, Karam V, Sobesky R, Vibert E, Coilly A, Maria Antonini T, De Martin E, Cherqui D, Baba H, Rosmorduc O, Adam R, Samuel D, Saliba F. High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients. Transpl Int 2021;34:1293-305. [PMID: 33932239 DOI: 10.1111/tri.13897] [Reference Citation Analysis]
161 Erstad DJ, Tanabe KK. Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:1474-93. [DOI: 10.1245/s10434-019-07227-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 14.7] [Reference Citation Analysis]
162 Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019;69:1324-36. [DOI: 10.1002/hep.30278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
163 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
165 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
166 Ersan V, Barut B, Yilmaz S. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait? J Gastrointest Cancer 2020;51:1152-6. [PMID: 32856230 DOI: 10.1007/s12029-020-00491-z] [Reference Citation Analysis]
167 Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402:863-871. [PMID: 28755240 DOI: 10.1007/s00423-017-1609-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
168 Mastrocostas K, Fischer S, Munoz-Schuffenegger P, Jang HJ, Dawson LA, Liu ZA, Sapisochin G, Kim TK. Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. Abdom Radiol (NY) 2021;46:1572-85. [PMID: 33074426 DOI: 10.1007/s00261-020-02821-y] [Reference Citation Analysis]
169 He JJ, Shang L, Yu QW, Jiao N, Qiu S, Zhu WX, Wu DF, Tian YE, Zhang Q. High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation. World J Gastrointest Oncol 2021; 13(7): 716-731 [PMID: 34322200 DOI: 10.4251/wjgo.v13.i7.716] [Reference Citation Analysis]